![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
November 16, 2021
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 17, 2021
This phase II study is testing the effects and safety of green tea catechins (GTC) as a chemopreventive agent
July 7, 2021
This phase II/III study is comparing the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery
May 28, 2021
Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present a wide range of research findings at the 2021 ASCO Annual Meeting
May 28, 2021
The EA8185 phase II trial is the first prospective study exclusively for patients with lymph node positive bladder cancer
March 31, 2021
February 25, 2021
January 25, 2021
This phase III study, led by Dr. Alicia Morgans, is exploring a new treatment option for patients with prostate cancer with high-risk features
December 14, 2020
The five phase III trials span different cancer types: prostate, leukemia, anal, lung, and myeloma
October 19, 2020
